Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q2

2784.TEDINET S100S6JK
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.43T2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥2.70T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥1.33T2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥16.0bn2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥10.2bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥17.3bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥32.8bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥17.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥11.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥11.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥25.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥11.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.43Tat 2023-09-30Cons.Assets
Total assets¥1.34Tat 2023-03-31Cons.Assets
Total assets¥1.33Tat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥960.7bnat 2023-09-30Cons.Liabilities
Total liabilities¥851.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥465.6bnat 2023-09-30Cons.Net assets
Net assets / equity¥488.3bnat 2023-03-31Cons.Net assets
Net assets / equity¥481.9bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥186.2bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥160.1bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥184.8bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥158.8bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥168.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥179.1bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥63.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥8.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥20.5bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥15.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥29.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥12.9bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥60.292023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥40.572023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥127.422022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥34.62022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.12022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio32.6%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥16.9bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥16.9bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30¥269m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.27T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.26T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥8.9bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥13.8bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥26.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥18.3bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥7.7bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥186m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥18.2bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥18.2bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥279m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥133.3bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥133.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥275m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥1.44T
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥1.43T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥16.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥15.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥245m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.18T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.17T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥8.3bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥23.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥842m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥14m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥124.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥123.8bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥305m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.35T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.33T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥15.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥10.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 538
ItemContextValueUnit
Interest income noiCurrentYTDDuration29000000JPY
Dividends income noiPrior1YTDDuration825000000JPY
Dividends income noiCurrentYTDDuration778000000JPY
Real estate rent noiPrior1YTDDuration297000000JPY
Real estate rent noiCurrentYTDDuration270000000JPY
Other noiPrior1YTDDuration330000000JPY
Other noiCurrentYTDDuration484000000JPY
Non operating incomePrior1YTDDuration1483000000JPY
Non operating incomeCurrentYTDDuration1561000000JPY
Interest expenses noePrior1YTDDuration34000000JPY
Interest expenses noeCurrentYTDDuration35000000JPY
Commission fee noePrior1YTDDuration－JPY
Commission fee noeCurrentYTDDuration69000000JPY
Rent expenses on real estates noePrior1YTDDuration93000000JPY
Rent expenses on real estates noeCurrentYTDDuration89000000JPY
Other noePrior1YTDDuration95000000JPY
Other noeCurrentYTDDuration85000000JPY
Non operating expensesPrior1YTDDuration222000000JPY
Non operating expensesCurrentYTDDuration280000000JPY
Ordinary incomePrior1YTDDuration11488000000JPY
Ordinary incomeCurrentYTDDuration17280000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration104000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration185000000JPY
Gain on sales of investment securities eiPrior1YTDDuration237000000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration341000000JPY
Extraordinary incomeCurrentYTDDuration185000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration15000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration19000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration37000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration74000000JPY
Impairment loss elPrior1YTDDuration1000000JPY
Impairment loss elCurrentYTDDuration4000000JPY
Loss on valuation of investment securities elPrior1YTDDuration695000000JPY
Loss on valuation of investment securities elCurrentYTDDuration11000000JPY
Other elPrior1YTDDuration5000000JPY
Other elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration755000000JPY
Extraordinary lossCurrentYTDDuration109000000JPY
Income before income taxesPrior1YTDDuration11074000000JPY
Income before income taxesCurrentYTDDuration17356000000JPY
Income taxes currentPrior1YTDDuration8035000000JPY
Income taxes currentCurrentYTDDuration7630000000JPY
Income taxes deferredPrior1YTDDuration-4005000000JPY
Income taxes deferredCurrentYTDDuration-2163000000JPY
Income taxesPrior1YTDDuration4029000000JPY
Income taxesCurrentYTDDuration5466000000JPY
Profit lossPrior1YTDDuration7045000000JPY
Profit lossCurrentYTDDuration11889000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration7001000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass